Ignite Creation Date:
2024-05-05 @ 11:20 AM
Last Modification Date:
2024-10-26 @ 9:04 AM
Study NCT ID:
NCT00004293
Status:
UNKNOWN
Last Update Posted:
2005-06-24
First Post:
1999-10-18
Brief Title:
Phase II Study of Glucocerebrosidase in Patients With Gaucher Disease
Sponsor:
National Center for Research Resources NCRR
Organization:
National Center for Research Resources NCRR
Study Overview
Official Title:
None
Status:
UNKNOWN
Status Verified Date:
2003-12
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
OBJECTIVES
I Evaluate the efficacy and toxicity of glucocerebrosidase enzyme therapy in patients with Gaucher disease
I Evaluate the efficacy and toxicity of glucocerebrosidase enzyme therapy in patients with Gaucher disease
Detailed Description:
PROTOCOL OUTLINE
Patients are treated with intravenous glucocerebrosidase every 2 weeks The dose is based on clinical severity of disease and response to therapy
Patients are treated with intravenous glucocerebrosidase every 2 weeks The dose is based on clinical severity of disease and response to therapy
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| UPITTS-M1230 | None | None | None |